New triple therapy targets stomach cancer after immunotherapy fails
NCT ID NCT07610629
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs—retlirafusp alfa, apatinib, and nab-paclitaxel—in 50 adults with advanced stomach or gastroesophageal junction cancer that has progressed after first-line immunotherapy. The goal is to see if the combination can shrink tumors or slow disease progression. Participants receive treatment every three weeks for up to two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Retlirafusp alfa (a protein that targets PD-L1 and TGF-β), apatinib (a pill that blocks blood vessel growth), and nab-paclitaxel (a chemotherapy drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced gastric cancer whose disease has worsened after initial immunotherapy.
- What could go wrong
- This is a small, early-phase study with no comparison group, so results may not be definitive. The combination may cause significant side effects, and it is not yet known if it will improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?